Core Insights - McKesson (MCK) is valued at $100.9 billion and operates in healthcare services and information technology across four segments [1] - The stock has shown strong technical momentum, gaining 9.12% since a "Buy" signal was issued on September 23 [2] - McKesson has reached an all-time high of $811.86 in intraday trading on October 27 [4] - The stock has a 100% "Buy" opinion from Barchart, with shares up nearly 60% over the past year [6] - Analyst sentiment is positive, with price targets reaching up to $984 despite some valuation concerns [6] Technical Indicators - McKesson has a Weighted Alpha of +52.53 and a Relative Strength Index (RSI) of 70.21 [7] - The stock recently traded at $810.29, with a 50-day moving average of $734.34 [7] - There is a technical support level around $803.12 [7] Financial Projections - Revenue is projected to grow by 13.88% this year and an additional 8.26% next year [8] - Earnings are estimated to increase by 16.00% this year and another 13.37% next year [8]

Merck & Co Inc MRK will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.The stock is down a painful 38.04% over the past year and has dropped 20.73% year-to-date. Even in the past month, it’s off by 14.85%, making it one of the more bruised names among Big Pharma peers.Let's look at what the charts indicate for Merck stock and how it currently maps against Wall Street estimates.Read Also: Gilead Cancer ...

Oracle Corp ORCL will be reporting its third-quarter earnings on Monday. Wall Street expects $1.49 in EPS and $14.39 billion in revenues as the company reports after market hours.The stock is up 29.73% over the past year, down 10.82% year-to-date.Let’s look at what the charts indicate for Oracle stock and how the stock currently maps against Wall Street estimates.Read Also: Oracle Q3 Earnings Preview: ‘Some Positive Signs And Good Risk/Reward’ Ahead Of PrintORCL Stock Strongly Bearish Ahead Of Q3 Earnings C ...